These two land in the same search results when people look into peptides for fat loss, which makes them easy to picture as alternatives. They really aren't. They target different parts of the problem, and just as importantly, they sit at opposite ends of the evidence spectrum. Putting them side by side is useful mainly because it shows how differently two compounds can earn the same "fat loss" label.
What AOD-9604 and semaglutide have in common
Honestly, not much beyond the goal. Both are discussed in the context of reducing body fat, and both are peptides delivered by injection. That's roughly where the overlap ends. They work through unrelated mechanisms, carry very different amounts of human evidence, and occupy different regulatory worlds. The shared "fat loss" framing is what brings them together, not any real similarity in how they work. It's a good reminder that two compounds can be marketed for the same outcome while being almost nothing alike underneath, which is exactly why looking at mechanism and evidence separately is worth the effort.
How AOD-9604 works
AOD-9604 is a fragment of human growth hormone, specifically the tail end of the molecule (the region thought to influence fat metabolism), engineered to keep that piece while dropping the rest. The idea was to capture growth hormone's fat-burning signal, encouraging the body to break down fat (lipolysis), without affecting blood sugar or IGF-1 the way full growth hormone does. It's a clever concept. The catch is that human clinical trials for obesity were underwhelming: AOD-9604 did not produce significant weight loss beyond placebo in the studies that tested it for that purpose. It's worth being clear-eyed about that, because the marketing rarely is.
How semaglutide works
Semaglutide takes an entirely different route. It's a GLP-1 receptor agonist, mimicking glucagon-like peptide-1, a gut hormone that signals fullness, slows digestion, and prompts insulin release. Rather than acting on fat tissue directly, it works largely through appetite: people eat less because they feel satisfied sooner and stay full longer. This approach has produced substantial, well-documented weight reduction across large clinical trials, and semaglutide is an FDA-approved prescription medication (sold as Wegovy and Ozempic), which sets it apart from most compounds discussed on this site.
Key differences
The mechanism gap is real but secondary to the evidence gap. AOD-9604 aims at fat metabolism directly; semaglutide aims at appetite. In principle those are complementary ideas. In practice, only one of them has strong human results behind it. Semaglutide's weight outcomes are among the best-documented in the field, while AOD-9604's are thin and, for obesity specifically, disappointing. If a decision rests on what the human data actually shows, that's the most important sentence in this article.
Side effects follow the same asymmetry. Semaglutide's are well-characterized, mostly digestive (nausea, and related stomach effects, especially while the dose is increased), precisely because it's been studied so thoroughly. AOD-9604 is generally described as well tolerated with few reported effects, but that partly reflects how little rigorous human data exists rather than a proven clean record. Fewer reported effects and fewer studies are not the same thing.
Regulatory status is the final divide. Semaglutide is approved, prescribed, and monitored. AOD-9604 has drifted through different classifications over the years and is sold today as a research compound, not approved for human use, with all the source-quality uncertainty that implies. So these two differ not just in how they work, but in how much we know and how they're obtained.
| AOD-9604 | Semaglutide | |
|---|---|---|
| Origin | Growth hormone fragment | GLP-1 receptor agonist |
| Target | Fat metabolism (lipolysis) | Appetite and fullness |
| Human evidence | Thin; weak for weight loss | Strong, well-documented |
| Side effects | Few reported, little data | Digestive, well-characterized |
| Status | Research compound, unapproved | FDA-approved prescription |
| Best for | Curiosity, not a primary plan | Evidence-backed weight reduction |
Bottom line
Semaglutide is the option with serious evidence behind it for actual weight reduction. If the goal is meaningful, documented fat loss and a prescriber is involved, this is the side of the comparison where the research lives. Its appetite-based mechanism and large trial record are why it reshaped this entire category.
AOD-9604 is better understood as an interesting concept than a dependable result. The fat-metabolism idea is appealing, and it may have a place in research, but its human evidence for weight loss is weak, and anyone expecting semaglutide-level outcomes from it is likely to be disappointed. If you're drawn to it, go in with realistic expectations and an awareness that the strongest claims about it tend to outrun the data. It's the kind of compound where reading the actual studies, rather than the product pages, changes the picture considerably.
Where to go from here
If GLP-1 medications are the direction that interests you, Semaglutide vs. Tirzepatide compares the two most popular ones head to head, and the GLP-1s explainer covers how the class works and what the major trials showed. For the broader context on preserving lean tissue during weight loss, the post on muscle loss on a GLP-1 is worth a read. To compare per-milligram vendor pricing, the Peptide Price Lab tool tracks the market in one place.